The Yuan requests your support! Our content will now be available free of charge for all registered subscribers, consistent with our mission to make AI a human commons accessible to all. We are therefore requesting donations from our readers so we may continue bringing you insightful reportage of this awesome technology that is sweeping the world. Donate now
(Bio)pharmas must advance more inclusive social agendas to build trust
By Tonny Huang, Keena Patel-Moran, Erik Blazic, Betty Pio  |  Aug 16, 2023
(Bio)pharmas must advance more inclusive social agendas to build trust
Image courtesy of and under license from
(Bio)pharma firms are well positioned to ensure equal access to treatment by fostering patient trust via equity-focused drug discovery, clinical trials, commercial strategy, and healthcare ecosystem enablement, argue four healthcare executives with global management firm Kearney.

DETROIT, BOSTON, SAN FRANCISCO, TORONTO - Environmental, social, and governance issues are important for many sectors and the life sciences industry is no exception.

Environmental activism has been in the works for decades but has recently gained greater traction and gathered momentum. This can be credited to a turning point in the alignment between governance, people, relationships, expertise, and data across the value chain, ultimately creating a sense of trust with patients and society (see the figure below).

Now is the time to create that trust for patients in healthcare, especially given that there is a growing segment of society that views it as a basic human right, in the same category as adequate access to nutritious food and clean water. Higher levels of patient trust correlate with increases in positive health outcomes, including improved adherence to medications, better experiences, and an increased use of available and effective health interventions - e.g., public health programs. As patient populations become increasingly diverse - while also enjoying greater access to care channels - it is more important than ever to clearly understand which groups are medically disadvantaged and then develop appropriate interventions to enable more equitable health outcomes.

Much of this patient trust is built as part of efforts to resolve social inequities related to individual patient health outcomes. Presently, although (bio)pharmaceutical companies are advancing ways to improve health equity, there is still an opportunity to create even more value for medically disadvantaged patient populations while also successfully operating within today’s regulatory and macroeconomic conditions.

Going forward, the (bio)pharma firms most likely to succeed will be those that develop patien

The content herein is subject to copyright by The Yuan. All rights reserved. The content of the services is owned or licensed to The Yuan. Such content from The Yuan may be shared and reprinted but must clearly identify The Yuan as its original source. Content from a third-party copyright holder identified in the copyright notice contained in such third party’s content appearing in The Yuan must likewise be clearly labeled as such.
Continue reading
Sign up now to read this story for free.
- or -
Continue with Linkedin Continue with Google
Share your thoughts.
The Yuan wants to hear your voice. We welcome your on-topic commentary, critique, and expertise. All comments are moderated for civility.